Statins and the brain: More than lipid lowering agents?

Anna Fracassi, Martina Marangoni, Pamela Rosso, Valentina Pallottini, Marco Fioramonti, Silvia Siteni, Marco Segatto

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Background: Statins represent a class of medications widely prescribed to efficiently treat dyslipidemia. These drugs inhibit 3-βhydroxy 3β-methylglutaryl Coenzyme A reductase (HMGR), the rate-limiting enzyme of mevalonate (MVA) pathway. Besides cholesterol, MVA pathway leads to the production of several other compounds, which are essential in the regulation of a plethora of biological activities, including in the central nervous system. For these reasons, statins are able to induce pleiotropic actions, and acquire increased interest as potential and novel modulators in brain processes, especially during pathological conditions. Objective: The purpose of this review is to summarize and examine the current knowledge about pharmacokinetic and pharmacodynamic properties of statins in the brain. In addition, effects of statin on brain diseases are discussed providing the most up-to-date information. Methods: Relevant scientific information was identified from PubMed database using the following keywords: statins and brain, central nervous system, neurological diseases, neurodegeneration, brain tumors, mood, stroke. Results: 315 scientific articles were selected and analyzed for the writing of this review article. Several papers highlighted that statin treatment is effective in preventing or ameliorating the symp-tomatology of a number of brain pathologies. However, other studies failed to demonstrate a neuroprotective effect. Conclusion: Even though considerable research studies suggest pivotal functional outcomes induced by statin therapy, additional investigation is required to better determine the pharmacological effectiveness of statins in the brain, and support their clinical use in the management of different neuropathologies.

Original languageEnglish (US)
Pages (from-to)59-83
Number of pages25
JournalCurrent Neuropharmacology
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2019
Externally publishedYes

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Brain
Mevalonic Acid
Central Nervous System Diseases
Brain Diseases
Neuroprotective Agents
Dyslipidemias
PubMed
Brain Neoplasms
Oxidoreductases
Central Nervous System
Pharmacokinetics
Stroke
Cholesterol
Databases
Pharmacology
Pathology
Enzymes

Keywords

  • Brain
  • Brain tumors
  • Mood
  • Neurodegeneration
  • Neurological disorders
  • Statins

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Fracassi, A., Marangoni, M., Rosso, P., Pallottini, V., Fioramonti, M., Siteni, S., & Segatto, M. (2019). Statins and the brain: More than lipid lowering agents? Current Neuropharmacology, 17(1), 59-83. https://doi.org/10.2174/1570159X15666170703101816

Statins and the brain : More than lipid lowering agents? / Fracassi, Anna; Marangoni, Martina; Rosso, Pamela; Pallottini, Valentina; Fioramonti, Marco; Siteni, Silvia; Segatto, Marco.

In: Current Neuropharmacology, Vol. 17, No. 1, 01.01.2019, p. 59-83.

Research output: Contribution to journalReview article

Fracassi, A, Marangoni, M, Rosso, P, Pallottini, V, Fioramonti, M, Siteni, S & Segatto, M 2019, 'Statins and the brain: More than lipid lowering agents?', Current Neuropharmacology, vol. 17, no. 1, pp. 59-83. https://doi.org/10.2174/1570159X15666170703101816
Fracassi A, Marangoni M, Rosso P, Pallottini V, Fioramonti M, Siteni S et al. Statins and the brain: More than lipid lowering agents? Current Neuropharmacology. 2019 Jan 1;17(1):59-83. https://doi.org/10.2174/1570159X15666170703101816
Fracassi, Anna ; Marangoni, Martina ; Rosso, Pamela ; Pallottini, Valentina ; Fioramonti, Marco ; Siteni, Silvia ; Segatto, Marco. / Statins and the brain : More than lipid lowering agents?. In: Current Neuropharmacology. 2019 ; Vol. 17, No. 1. pp. 59-83.
@article{cd583838838c434ca74c034f6e57b5b7,
title = "Statins and the brain: More than lipid lowering agents?",
abstract = "Background: Statins represent a class of medications widely prescribed to efficiently treat dyslipidemia. These drugs inhibit 3-βhydroxy 3β-methylglutaryl Coenzyme A reductase (HMGR), the rate-limiting enzyme of mevalonate (MVA) pathway. Besides cholesterol, MVA pathway leads to the production of several other compounds, which are essential in the regulation of a plethora of biological activities, including in the central nervous system. For these reasons, statins are able to induce pleiotropic actions, and acquire increased interest as potential and novel modulators in brain processes, especially during pathological conditions. Objective: The purpose of this review is to summarize and examine the current knowledge about pharmacokinetic and pharmacodynamic properties of statins in the brain. In addition, effects of statin on brain diseases are discussed providing the most up-to-date information. Methods: Relevant scientific information was identified from PubMed database using the following keywords: statins and brain, central nervous system, neurological diseases, neurodegeneration, brain tumors, mood, stroke. Results: 315 scientific articles were selected and analyzed for the writing of this review article. Several papers highlighted that statin treatment is effective in preventing or ameliorating the symp-tomatology of a number of brain pathologies. However, other studies failed to demonstrate a neuroprotective effect. Conclusion: Even though considerable research studies suggest pivotal functional outcomes induced by statin therapy, additional investigation is required to better determine the pharmacological effectiveness of statins in the brain, and support their clinical use in the management of different neuropathologies.",
keywords = "Brain, Brain tumors, Mood, Neurodegeneration, Neurological disorders, Statins",
author = "Anna Fracassi and Martina Marangoni and Pamela Rosso and Valentina Pallottini and Marco Fioramonti and Silvia Siteni and Marco Segatto",
year = "2019",
month = "1",
day = "1",
doi = "10.2174/1570159X15666170703101816",
language = "English (US)",
volume = "17",
pages = "59--83",
journal = "Current Neuropharmacology",
issn = "1570-159X",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Statins and the brain

T2 - More than lipid lowering agents?

AU - Fracassi, Anna

AU - Marangoni, Martina

AU - Rosso, Pamela

AU - Pallottini, Valentina

AU - Fioramonti, Marco

AU - Siteni, Silvia

AU - Segatto, Marco

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Statins represent a class of medications widely prescribed to efficiently treat dyslipidemia. These drugs inhibit 3-βhydroxy 3β-methylglutaryl Coenzyme A reductase (HMGR), the rate-limiting enzyme of mevalonate (MVA) pathway. Besides cholesterol, MVA pathway leads to the production of several other compounds, which are essential in the regulation of a plethora of biological activities, including in the central nervous system. For these reasons, statins are able to induce pleiotropic actions, and acquire increased interest as potential and novel modulators in brain processes, especially during pathological conditions. Objective: The purpose of this review is to summarize and examine the current knowledge about pharmacokinetic and pharmacodynamic properties of statins in the brain. In addition, effects of statin on brain diseases are discussed providing the most up-to-date information. Methods: Relevant scientific information was identified from PubMed database using the following keywords: statins and brain, central nervous system, neurological diseases, neurodegeneration, brain tumors, mood, stroke. Results: 315 scientific articles were selected and analyzed for the writing of this review article. Several papers highlighted that statin treatment is effective in preventing or ameliorating the symp-tomatology of a number of brain pathologies. However, other studies failed to demonstrate a neuroprotective effect. Conclusion: Even though considerable research studies suggest pivotal functional outcomes induced by statin therapy, additional investigation is required to better determine the pharmacological effectiveness of statins in the brain, and support their clinical use in the management of different neuropathologies.

AB - Background: Statins represent a class of medications widely prescribed to efficiently treat dyslipidemia. These drugs inhibit 3-βhydroxy 3β-methylglutaryl Coenzyme A reductase (HMGR), the rate-limiting enzyme of mevalonate (MVA) pathway. Besides cholesterol, MVA pathway leads to the production of several other compounds, which are essential in the regulation of a plethora of biological activities, including in the central nervous system. For these reasons, statins are able to induce pleiotropic actions, and acquire increased interest as potential and novel modulators in brain processes, especially during pathological conditions. Objective: The purpose of this review is to summarize and examine the current knowledge about pharmacokinetic and pharmacodynamic properties of statins in the brain. In addition, effects of statin on brain diseases are discussed providing the most up-to-date information. Methods: Relevant scientific information was identified from PubMed database using the following keywords: statins and brain, central nervous system, neurological diseases, neurodegeneration, brain tumors, mood, stroke. Results: 315 scientific articles were selected and analyzed for the writing of this review article. Several papers highlighted that statin treatment is effective in preventing or ameliorating the symp-tomatology of a number of brain pathologies. However, other studies failed to demonstrate a neuroprotective effect. Conclusion: Even though considerable research studies suggest pivotal functional outcomes induced by statin therapy, additional investigation is required to better determine the pharmacological effectiveness of statins in the brain, and support their clinical use in the management of different neuropathologies.

KW - Brain

KW - Brain tumors

KW - Mood

KW - Neurodegeneration

KW - Neurological disorders

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=85058921442&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058921442&partnerID=8YFLogxK

U2 - 10.2174/1570159X15666170703101816

DO - 10.2174/1570159X15666170703101816

M3 - Review article

C2 - 28676012

AN - SCOPUS:85058921442

VL - 17

SP - 59

EP - 83

JO - Current Neuropharmacology

JF - Current Neuropharmacology

SN - 1570-159X

IS - 1

ER -